Elraglusib by Actuate Therapeutics for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

Ohio State study reveals bacterial defense mechanism against phages

One of the many secrets to bacteria’s success is their ability to defend themselves from viruses, called phages, that infect bacteria and use their cellular

April 27, 2024

Psyence Expands Psilocybin Production Capability | Psychedelic Invest

Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to

November 3, 2023

Addressing industry challenges with personalized eCOA solutions

eCOA technology can help to improve the patient experience. Credit: fizkes via Shutterstock. Electronic clinical outcome assessment (eCOA) has become an essential tool for capturing

August 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.